FDA Approves First Generic Versions of Antidepressant Drug Cymbalta

FDA has approved the first generic versions of Cymbalta (duloxetine delayed-release capsules), a prescription medicine used to treat depression and other conditions.
Aurobindo Pharma Ltd, Dr Reddy’s Laboratories Ltd, Lupin Ltd, Sun Pharma Global FZE, Teva Pharmaceuticals USA, and Torrent Pharmaceuticals Ltd have received FDA approval to market duloxetine in various strengths.
“Healthcare professionals and consumers can be assured that these FDA-approved generic drugs have met our rigorous standards,” said Kathleen Uhl, MD, acting director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research. “Generic drugs offer greater access to healthcare for many people.”
Depression is characterised by symptoms that interfere with a person's ability to work, sleep, study, eat and enjoy once-pleasurable activities. Episodes of depression often recur throughout a person's lifetime. Signs and symptoms of depression include: depressed mood, loss of interest in usual activities, significant change in weight or appetite, insomnia or excessive sleeping (hypersomnia), restlessness/pacing (psychomotor agitation), increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicide attempts or thoughts of suicide.
Duloxetine and other antidepressant drugs have a boxed warning describing the increased risk of suicidal thinking and behavior during initial treatment in children, adolescents, and young adults ages 18 to 24. The warning also says data do not show this increased risk in those older than 24 years and that patients ages 65 and older who take antidepressants have a decreased risk of suicidal thinking and behaviour.
The warning says depression and other serious psychiatric disorders themselves are the most important causes of suicide and that close monitoring of patients starting these medications is necessary. Duloxetine must be dispensed with a patient medication guide that describes important information about the drug’s uses and risks.
Related News
-
News South Korea's Seegene develops PCR test to detect monkeypox virus
Several countries are stepping up vaccination and testing as monkeypox cases continue to climb -
News EMA starts rolling review of Moderna’s Omicron-targeting vaccine, as well as Pfizer-BioNTech rival
The vaccines have been adapted to target the Omicron variant, which has been the dominant variant globally since the beginning of the year -
News Evotec enters drug discovery collaboration with Janssen Pharmaceutica NV
Evotec and Janssen Pharmaceutica team up to discover novel therapeutic candidates -
News BioNTech to start work on first African mRNA vaccine factory this month
The Rwanda site will be the first piece of the company’s African manufacturing network -
News Integrated service partners outperform standalone CDMOs in clinical development – Thermo Fisher
Engaging an integrated services partner could reduce risk and speed-up the process for drug sponsors. -
News Thermo Fisher and Charles River join consortium using robotics to produce cell therapies at scale
The Consortium aims to increase the scale of cell therapy manufacturing to a level impossible with current manual processes. -
News Onyx Scientific expands small molecule CMC services with new UK facility
The contract development and manufacturing organisation (CDMO) has completed the first phase of its multi-million-pound development. -
News Roche latest to report trial delays due to Ukraine war
The war in Ukraine has forced companies to suspend or delay clinical trials in the region.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance